Loading...

Rettig, Matthew B

Title(s)Professor-in-Residence, Medicine
Phone43565
vCardDownload vCard
    Other Positions
    Title(s)Professor-in-Residence, Urology


    Collapse Research 
    Collapse Research Activities and Funding
    A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
    VA I01CX002006Apr 1, 2020 - Mar 31, 2023
    Role: Principal Investigator
    HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma
    VA I01BX002778Oct 1, 2015 - Sep 30, 2019
    Role: Principal Investigator
    Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
    NIH/NCI R01CA164331Sep 26, 2012 - Jul 31, 2017
    Role: Principal Investigator
    Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
    VA I01CX000324Oct 1, 2011 - Sep 30, 2015
    Role: Principal Investigator
    Targeting Androgen Receptor Activity in Prostate Cancer
    NIH/NCI R21CA113351Feb 1, 2006 - Jan 31, 2009
    Role: Principal Investigator
    Increased IL6 Transcription by HHV8
    NIH/NCI R01CA080004Mar 15, 2002 - Feb 28, 2008
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hao Q, Diaz T, Verduzco ADR, Magyar CE, Zhong J, Elshimali Y, Rettig MB, Henning SM, Vadgama JV, Wang P. Arctigenin inhibits prostate tumor growth in high-fat diet fed mice through dual actions on adipose tissue and tumor. Sci Rep. 2020 Jan 29; 10(1):1403. PMID: 31996731.
      View in: PubMed
    2. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2020 Feb; 77(2):201-208. PMID: 31718822.
      View in: PubMed
    3. An Q, Hu Y, Li Q, Chen X, Huang J, Pellegrini M, Zhou XJ, Rettig M, Fan G. The size of cell-free mitochondrial DNA in blood is inversely correlated with tumor burden in cancer patients. Precis Clin Med. 2019 Sep; 2(3):131-139. PMID: 31598384.
      View in: PubMed
    4. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 Sep; 20(9):1286-1294. PMID: 31375469.
      View in: PubMed
    5. Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019 05 15; 79(10):2580-2592. PMID: 30952632.
      View in: PubMed
    6. Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 01; 19(1):291. PMID: 30935383.
      View in: PubMed
    7. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. PMID: 30804427.
      View in: PubMed
    8. Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. Eur Urol Oncol. 2019 Feb 01. PMID: 31411981.
      View in: PubMed
    9. Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018 Oct 29; 8(1):96. PMID: 30374743.
      View in: PubMed
    10. Dhar M, Lam JN, Walser T, Dubinett SM, Rettig MB, Di Carlo D. Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):9986-9991. PMID: 30224472.
      View in: PubMed
    11. Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. J Nucl Med. 2018 09; 59(9):1392-1397. PMID: 29602819.
      View in: PubMed
    12. Liu S, Cadaneanu RM, Zhang B, Huo L, Lai K, Li X, Galet C, Grogan TR, Elashoff D, Freedland SJ, Rettig M, Aronson WJ, Knudsen BS, Lewis MS, Garraway IP. Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone. PLoS One. 2016; 11(10):e0163232. PMID: 27711225.
      View in: PubMed
    13. Murray C, Pao E, Tseng P, Aftab S, Kulkarni R, Rettig M, Di Carlo D. Quantitative Magnetic Separation of Particles and Cells Using Gradient Magnetic Ratcheting. Small. 2016 Apr 13; 12(14):1891-9. PMID: 26890496.
      View in: PubMed
    14. Nguyen KL, Alrezk R, Mansourian PG, Naeim A, Rettig MB, Lee CC. The Crossroads of Geriatric Cardiology and Cardio-Oncology. Curr Geriatr Rep. 2015; 4(4):327-337. PMID: 26543801.
      View in: PubMed
    15. An J, Guo Y, Wang T, Pantuck AJ, Rettig MB. Pomegranate extract inhibits EMT in clear cell renal cell carcinoma in a NF-?B and JNK dependent manner. Asian J Urol. 2015 Jan; 2(1):38-45. PMID: 29264118.
      View in: PubMed
    16. Gollapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J, Elashoff D, Freedland SJ, Rettig M, Aronson WJ. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res. 2013; 3(5):523-9. PMID: 24224130.
      View in: PubMed
    17. Sollier E, Go DE, Che J, Gossett DR, O'Byrne S, Weaver WM, Kummer N, Rettig M, Goldman J, Nickols N, McCloskey S, Kulkarni RP, Di Carlo D. Size-selective collection of circulating tumor cells using Vortex technology. Lab Chip. 2014 Jan 07; 14(1):63-77. PMID: 24061411.
      View in: PubMed
    18. Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM. NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods. 2013 Dec 01; 64(2):144-52. PMID: 23816790.
      View in: PubMed
    19. Zhao L, Lu YT, Li F, Wu K, Hou S, Yu J, Shen Q, Wu D, Song M, OuYang WH, Luo Z, Lee T, Fang X, Shao C, Xu X, Garcia MA, Chung LW, Rettig M, Tseng HR, Posadas EM. High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing. Adv Mater. 2013 Jun 04; 25(21):2897-902. PMID: 23529932.
      View in: PubMed
    20. An J, Liu H, Magyar CE, Guo Y, Veena MS, Srivatsan ES, Huang J, Rettig MB. Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma. Cancer Res. 2013 Feb 15; 73(4):1374-85. PMID: 23393199.
      View in: PubMed
    21. Mortazavi F, Dubinett S, Rettig M. c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells. Clin Exp Metastasis. 2011 Apr; 28(4):391-404. PMID: 21336985.
      View in: PubMed
    22. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010 Dec; 16(12):1414-20. PMID: 21057494.
      View in: PubMed
    23. Mortazavi F, An J, Dubinett S, Rettig M. p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells. Mol Cancer Res. 2010 May; 8(5):762-74. PMID: 20460685.
      View in: PubMed
    24. Pantuck AJ, An J, Liu H, Rettig MB. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Cancer Res. 2010 Jan 15; 70(2):752-61. PMID: 20068166.
      View in: PubMed
    25. An J, Mo D, Liu H, Veena MS, Srivatsan ES, Massoumi R, Rettig MB. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell. 2008 Nov 04; 14(5):394-407. PMID: 18977328.
      View in: PubMed
    26. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldegrun A, Moro A, Henning SM, Mo D, Aronson WJ, Pantuck A. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther. 2008 Sep; 7(9):2662-71. PMID: 18790748.
      View in: PubMed
    27. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, Firouzi A, Rettig MB, Aronson WJ, Pantuck AJ, Heber D. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol. 2008 Feb; 32(2):475-80. PMID: 18202771.
      View in: PubMed
    28. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem. 2007 Sep 19; 55(19):7732-7. PMID: 17722872.
      View in: PubMed
    29. An J, Rettig MB. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther. 2007 Jan; 6(1):61-9. PMID: 17237266.
      View in: PubMed
    30. An J, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol. 2005 Sep; 25(17):7546-56. PMID: 16107702.
      View in: PubMed
    31. An J, Fisher M, Rettig MB. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. Oncogene. 2005 Feb 24; 24(9):1563-70. PMID: 15608669.
      View in: PubMed
    32. Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004 Aug; 64(2):335-40. PMID: 15302490.
      View in: PubMed
    33. An J, Sun Y, Fisher M, Rettig MB. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther. 2004 Jun; 3(6):727-36. PMID: 15210859.
      View in: PubMed
    34. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004 Jan 23; 279(4):2737-46. PMID: 14576155.
      View in: PubMed
    35. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res. 2003 Oct 01; 9(12):4537-45. PMID: 14555528.
      View in: PubMed
    36. An J, Sun Y, Rettig MB. Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. Blood. 2004 Jan 01; 103(1):222-8. PMID: 12969971.
      View in: PubMed
    37. An J, Sun Y, Sun R, Rettig MB. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene. 2003 May 29; 22(22):3371-85. PMID: 12776188.
      View in: PubMed
    38. Deng H, Chu JT, Rettig MB, Martinez-Maza O, Sun R. Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression. Blood. 2002 Sep 01; 100(5):1919-21. PMID: 12176919.
      View in: PubMed
    39. An J, Lichtenstein AK, Brent G, Rettig MB. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood. 2002 Jan 15; 99(2):649-54. PMID: 11781250.
      View in: PubMed